Disorders of the Respiratory System

Comprehensive clinical notes covering the etiology, pathophysiology, clinical presentation, and management of major respiratory conditions: Asthma, Pneumonia, and Emphysema.

1. Asthma

Asthma is a chronic inflammatory disorder of the airways characterized by reversible airflow obstruction, bronchial hyperresponsiveness, and airway remodeling. It affects approximately 262 million people worldwide and is a leading cause of morbidity in children and young adults.

1.1 Definition and Epidemiology

Nature: Chronic condition with variable and recurring symptoms and reversible airflow limitation.
Prevalence: 5–10% globally; notably higher in developed countries and urban areas.
Onset: Frequently in childhood; may persist or remit and relapse later in life.

1.2 Etiology and Risk Factors

Atopic (allergic) asthma: Most common form; associated with IgE-mediated hypersensitivity to allergens such as dust mites, pollen, pet dander, and mold.
Non-atopic asthma: Triggered by infections, irritants, exercise, cold air, or stress; involves no allergen sensitization.
Occupational asthma: Caused by workplace exposures to isocyanates, flour, wood dust, or chemicals.
Risk Factors: Family history of atopy, childhood respiratory infections, obesity, smoking, air pollution, and low birth weight.

1.3 Pathophysiology

Acute phase: Allergen exposure triggers IgE-mediated mast cell degranulation, releasing histamine, leukotrienes, prostaglandins, and cytokines.
Bronchoconstriction: Smooth muscle contraction narrows airways within minutes.
Mucus hypersecretion: Goblet cell hyperplasia and submucosal gland hypertrophy produce thick, tenacious mucus plugs.
Airway edema: Increased vascular permeability causes mucosal swelling.
Chronic inflammation: Eosinophils, T-helper 2 (Th2) cells, mast cells, and neutrophils infiltrate the airway wall.
Airway remodeling: Subepithelial fibrosis, smooth muscle hypertrophy, and basement membrane thickening cause irreversible airflow limitation in long-standing disease.

Figure: Asthma Pathophysiology — Comparison of a normal airway with an inflamed, constricted airway showing mucus and muscle tightening.

1.4 Clinical Features

Classic triad: Wheeze, cough, and dyspnea.

Symptoms: Variable, often worse at night or early morning; triggered by exercise, allergens, or cold air.
Physical examination: Prolonged expiratory phase, bilateral wheezing, use of accessory muscles, tachypnea, and tachycardia.

Red Flag

Severe Acute Asthma

Signs of a life-threatening attack include a Silent chest (absence of wheeze due to minimal airflow), cyanosis, altered consciousness, exhaustion, and bradycardia (a pre-arrest sign).

1.5 Diagnosis

History: Pattern of symptoms, specific triggers, and family history.
Spirometry: Reduced FEV₁ and FEV₁/FVC ratio (<0.70). Diagnosis is supported by significant reversibility (increase in FEV₁ >12% and >200 mL after bronchodilator).

1.7 Management

Stepwise Approach (GINA Guidelines):

Step 1: SABA as needed.
Step 2: Low-dose Inhaled Corticosteroid (ICS) daily + SABA.
Step 3: Low-dose ICS/LABA combination or medium-dose ICS.
Step 4: Medium-dose ICS/LABA.
Step 5: High-dose ICS/LABA + add-on therapy (LAMA, biologics).

Clinical Scenario

Status Asthmaticus (Acute Severe Asthma)

Requires urgent hospitalization. Management includes:
— Continuous nebulized salbutamol + ipratropium bromide.
— Systemic corticosteroids (Oral prednisolone or IV hydrocortisone).
— Oxygen to maintain SpO₂ 94–98%.
— IV Magnesium sulfate for bronchodilator effect.
— Mechanical ventilation if refractory.

2. Pneumonia

Pneumonia is an acute infection of the lung parenchyma, including the alveolar spaces and interstitial tissue. It is a major cause of mortality worldwide, particularly in children under 5 and the elderly.

2.1 Classification

Category	Definition / Key Feature
CAP	Community-acquired; acquired outside healthcare facilities.
HAP	Hospital-acquired; occurs >48 hours after admission.
VAP	Ventilator-associated; occurs >48 hours after intubation.
Lobar	Consolidation of an entire lobe (typically S. pneumoniae).
Interstitial	Inflammation confined to alveolar walls (typical of viruses/Mycoplasma).

2.3 Etiology

Pathogen	Characteristics	Risk Factors
S. pneumoniae	Most common cause of CAP; Lobar consolidation.	Alcoholism, COPD, asplenia.
H. influenzae	Common cause of bronchopneumonia.	COPD, smoking, elderly.
Staph. aureus	Necrotizing pneumonia; Abscesses.	Post-influenza infection, IV drug use.
K. pneumoniae	Currant jelly sputum; Bulging fissure sign.	Alcoholism, Diabetes.
M. pneumoniae	Atypical; interstitial pattern.	Young adults, schools/military.
Legionella	Atypical; Hyponatremia; GI symptoms.	AC systems, hotels, smokers.

Figure: Chest X-Ray showing Lobar Consolidation in the right upper lobe, characteristic of Pneumococcal Pneumonia.

2.7 Management

General measures: Oxygen to maintain SpO₂ >94% (88–92% in COPD); hydration; analgesia.
Antibiotic Therapy (Empirical):
— Low risk CAP: Amoxicillin 500 mg TDS for 5 days.
— Moderate CAP: Amoxicillin-clavulanate + macrolide.
— ICU CAP: Ceftriaxone + azithromycin.

Complications

Untreated pneumonia can lead to Pleural effusion, Empyema, Lung abscess, Septicemia, and ARDS.

3. Emphysema

Emphysema is a form of COPD characterized by the permanent enlargement of airspaces distal to the terminal bronchioles, accompanied by destruction of alveolar walls without significant fibrosis.

3.2 Etiology and Risk Factors

Cigarette smoking: Accounts for 80–90% of cases.
Alpha-1 antitrypsin (AAT) deficiency: Genetic cause; AAT inhibits neutrophil elastase. Homozygous ZZ genotype causes early-onset panacinar emphysema.
Air pollution: Indoor biomass fuel exposure.

3.3 Pathophysiology

Protease-antiprotease imbalance: Neutrophil/macrophage proteases (elastase) destroy alveolar walls.
Alveolar wall destruction: Loss of elastic fibers and capillary beds; airspaces enlarge and coalesce.
Airway collapse: Loss of elastic recoil causes airways to collapse during expiration, leading to dynamic hyperinflation.
V/Q mismatch: Reduced surface area causes hypoxemia.

3.4 Types of Emphysema

Type	Location	Associations
Centriacinar	Central part of acinus; Upper lobes.	Cigarette smoking.
Panacinar	Entire acinus; Lower lobes.	AAT deficiency.
Paraseptal	Distal acinus near pleura.	Spontaneous pneumothorax; Subpleural bullae.

Figure: Emphysema Pathophysiology — Diagram showing the destruction of alveolar walls and loss of elastic tissue compared to normal lung tissue.

3.6 Diagnosis

Clinical hallmark: Progressive dyspnea, initially on exertion.
Spirometry: Irreversible obstruction (FEV₁/FVC <0.70).
Chest X-ray: Hyperinflation, flattened diaphragms, increased retrosternal airspace, and a small heart shadow.
CT Chest: Gold standard for detecting low-attenuation areas and bullae.

Long-Term Management

Oxygen therapy (LTOT): Indicated if PaO₂ ≤55 mmHg. Must be used >15 hours/day to improve survival.

Surgical options: Bullectomy (removal of large bullae) or Lung Volume Reduction Surgery (LVRS).

4. Key Points Summary

Asthma: Reversible airway obstruction; managed with ICS and SABA.
Pneumonia: Infection of parenchyma; CURB-65 guides assessment and antibiotic choice.
Emphysema: Alveolar wall destruction and loss of recoil; smoking is the primary cause.
Red Flag: The Silent Chest in an asthma attack is a medical emergency indicating near-total absence of airflow.

Doctors Revision